Initiate the Phase 2 HARBOR trial of BLU-263 in patients with non-advanced SM
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate the Phase 2 HARBOR trial of BLU-263 in patients with non-advanced SM in mid-2021”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2/3 HARBOR trial of BLU-263 in patients with non-advanced systemic mastocytosis during the second quarter of 2021, meeting the mid-2021 deadline.
-
A Blueprint Medicines Corp 10-K filed 2022-02-17
“Based on these data, we initiated the Phase 2/3 HARBOR trial of BLU-263 in patients with non-advanced SM in the second quarter of 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- HARBOR trial initiation
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Blueprint Medicines Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C597264-021772 · Corrections policy